HNSCC
Clinical trials for HNSCC explained in plain language.
Never miss a new study
Get alerted when new HNSCC trials appear
Sign up with your email to follow new studies for HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets tough head and neck cancers
Disease control CompletedThis study tested a combination of two drugs, tipifarnib and alpelisib, in 45 adults with advanced head and neck cancer that had spread or come back. The cancer had to have certain genetic changes (HRAS or PIK3CA). The goal was to see if the combo was safe and could shrink tumors…
Matched conditions: HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 03:20 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combo could shrink tumors or slow the disease. Patients were grouped based on whether they had tried…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
Two-Drug immune attack shows promise against tough cancers
Disease control CompletedThis study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 adults with advanced non-small cell lung cancer or head and neck cancer that had not responded to prior treatment. The goal was to see if the combo could shrink tumors safely. …
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-stage study tested a new drug called COM902, alone or with another drug (COM701), in 94 people with advanced cancers like ovarian, lung, or colon cancer. The main goals were to check safety, find the best dose, and see if the drugs help control the disease. Participant…
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated May 26, 2026 03:05 UTC
-
Immunotherapy boost may delay head and neck cancer return
Disease control CompletedThis study looked at whether adding the immunotherapy drug pembrolizumab to standard chemoradiation after surgery could help people with advanced head and neck cancer stay cancer-free longer. About 211 participants who had their tumor completely removed were randomly assigned to …
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New drug combo shows promise against hard-to-treat head and neck cancer
Disease control CompletedThis study tested whether adding an experimental drug (eftilagimod alpha) to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced head and neck cancer that cannot be removed by surgery. About 171 adults with PD-L1 positive or…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Can a common supplement reduce chemo pain? small study hopes to find out
Symptom relief CompletedThis early-phase study tested alpha lipoic acid, a dietary supplement, in 5 people with head and neck cancer undergoing chemoradiation. The goal was to find a safe dose that might reduce treatment-related pain and side effects. Researchers looked for the highest dose without seri…
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated May 26, 2026 03:15 UTC
-
Cancer patients may not need lifelong immunotherapy: landmark study tests stopping at one year
Knowledge-focused CompletedThis study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…
Matched conditions: HNSCC
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC